Autoimmune Diseases  >>  Lucentis (ranibizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lucentis (ranibizumab) / Roche, Novartis
NCT00931489: Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

Completed
2
131
US
ranibizumab (Lucentis(R)), Lucentis(R)
Lawrence S. Morse, MD, Genentech, Inc.
Age Related Macular Degeneration
06/14
06/14

Download Options